OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Neuropathic Corneal Pain
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
    • NCP Expanded Access
  • Technology
    • Chemerin Receptor
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

by Paul | 10th July 2024 | News

Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represent...

Recent Posts

  • OKYO Pharma to Present at BIO-Europe 2025 in Vienna
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
  • OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
  • OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023